Kimihiro leads the growing rare disease business unit in Japan. He joined Alexion in 2014 as a head of the Metabolic Disorder Business Unit, and was appointed General Manager in 2019. Before joining Alexion, he served as head of the Medical Affairs division at UCB for six years, and led development programs and teams at Banyu for eight years. Prior to joining the pharmaceutical industry, he served as a clinical practitioner, researcher, and teacher in hospitals and academic centers for 16 years. He is a psychiatrist by training with subspecialities in neurophysiology, psychopharmacology, and epileptology.
Kimihiro received his MD from Asahikawa Medical University, and PhD from Nihon University.